Probably because of this: Delandistrogene moxeparvovec was approved for medical use in the United States in June 2023.[3][7] It was developed by Sarepta Therapeutics, together with Roche, and is manufactured by Catalent.[8]
It's not the same drug for the latest death this article is focused on...
"Phase I study of SRP-9004".
It's not the same drug for the latest death this article is focused on...
"Phase I study of SRP-9004".